<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04732416</url>
  </required_header>
  <id_info>
    <org_study_id>HM-GCG-201</org_study_id>
    <nct_id>NCT04732416</nct_id>
  </id_info>
  <brief_title>HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)</brief_title>
  <official_title>A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and&#xD;
      efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent&#xD;
      hypoglycemia while on standard of care treatment (SoC). HM15136 will be administered once&#xD;
      weekly in multiple doses to subjects in multiple age including pediatric to find appropriate&#xD;
      exposure-response data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">April 14, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 14, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of incidence of AEs, TEAE, SAE as assessed by CTCAE v5.0</measure>
    <time_frame>after multiple subcutaneous (SC) doses of 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of incidence of clinical laboratory abnormalities</measure>
    <time_frame>after multiple subcutaneous (SC) doses of 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Serum Concentration [Cmax]</measure>
    <time_frame>after multiple subcutaneous (SC) doses of 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax</measure>
    <time_frame>after multiple subcutaneous (SC) doses of 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Congenital Hyperinsulinism</condition>
  <arm_group>
    <arm_group_label>HM15136 active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A / Cohort C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM15136</intervention_name>
    <description>Low dose of HM15136/ High dose of HM15136, SC injection, weekly</description>
    <arm_group_label>HM15136 active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects aged ≥2 years with CHI with persistent hypoglycemia despite&#xD;
             current SoC treatment according to the investigator's evaluation or documentation&#xD;
&#xD;
          -  Stable therapy with SoC medications with or without nutritional supplementation&#xD;
&#xD;
          -  Previously undergone near-total pancreatectomy or being treated with a nonsurgical&#xD;
             approach, having been evaluated as not eligible for pancreatic surgery&#xD;
&#xD;
          -  HbA1c &lt;7%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with type 1 or type 2 diabetes mellitus&#xD;
&#xD;
          -  Other reasons for hypoglycemia, including but not limited to drug-induced&#xD;
             hyperinsulinemic hypoglycemia, etc&#xD;
&#xD;
          -  Treatment of CHI with continuous intravenous glucose or glucagon infusion within 3&#xD;
             months prior to screening&#xD;
&#xD;
          -  Subjects with current use of any drugs that are known to interfere with the study&#xD;
             drug, glucose metabolism, or study procedures (eg, use of systemic glucocorticoids&#xD;
             [excluding topical, intra-articular or ophthalmic application, nasal spray, or inhaled&#xD;
             forms] or insulin)&#xD;
&#xD;
          -  Have conditions that could affect glucose levels such as pheochromocytoma, insulinoma,&#xD;
             and glucagonoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eunkyoung Oh</last_name>
    <phone>+82 2 410 0370</phone>
    <email>eunkyoung.oh@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Erin Okawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Ana Maria Arbelaez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Diva De Leon-Crutchlow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Kummer</last_name>
    </contact>
    <investigator>
      <last_name>Sebastian Kummer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke-Universitaet Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Klaus Mohnike</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital (GOSH) for Children NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Antonia Dastamani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospitals NHS Foundation Trust - Royal Manchester Children's Hospital - Centre for Paediatrics and Child Health</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Indi Banerjee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
    <mesh_term>Hyperinsulinism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

